|
Ceftazidime
Ceftazidime (Tazidime)
Ceftazidime
(sef-
TAY-zih-deem)
Pregnancy Category: B
Ceptaz
Fortaz
Tazicef
Tazidime
(Rx)
Classification:
Cephalosporin, third-generation
See Also:
See also
Anti-Infectives
[ and
Cephalosporins
][.
]
Action/Kinetics:
Only for IM or IV use.
t
1/2: 114-120 min. From 80% to 90% is excreted unchanged in the urine.
Uses:
(1) Lower respiratory tract infections (including pneumonia) due to
Pseudomonas aeruginosa and other
Pseudomonas species,
Haemophilus influenzae (including ampicillin-resistant strains),
Klebsiella species,
Enterobacter species,
Proteus mirabilis, Escerichia coli, Serratia species,
Citrobacter species,
Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible strains). (2) Skin and skin structure infections due to
P. aeruginosa, Klebsiella species,
E. coli, Proteus species (including
P. mirabilis and indole-positive
Proteus),
Enterobacter species,
Serratia species,
S. aureus (methicillin-susceptible strains),
S. pyogenes (group A �-hemolytic streptococci). (3) UTIs, both complicated and uncomplicated, due to
P. aeruginosa, Enterobacter species,
Proteus species (including
P. mirabilis and indole-positive
Proteus),
Klebsiella species, and
E. coli. Bacterial septicemia due to
P. aeruginosa, Klebsiella species,
H. influenzae, E. coli, Serratia species,
S. pneumoniae, S. aureus (methicillin-susceptible strains). (4) Bone and joint infections due to
P. aeruginosa, Klebsiella species,
Enterobacter species,
S. aureus (methicillin-susceptible strains). (5) GYN infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract, due to
E. coli. (6) Intra-abdominal infections, including peritonitis, due to
E. coli, Klebsiella species,
S. aureus (methicillin-susceptible strains); polymicrobial infections due to aerobic and anaeraobic organisms and
Bacteroides species (many strains of
B. fragilis are resistant). (7) CNS infections, including meningitis, due to
H. influenzae and
Neisseria meningitidis (limited effect against
P. aeruginosa and
S. pneumoniae).
Note: May be used with aminoglycosides, vancomycin, and clindamycin in severe and life-threatening infections and in the immunocompromised client.
Special Concerns:
A sodium carbonate formulation should be used if the drug is indicated for children less than 12 years of age. Possible resistance when used to treat
Pseudomonas aeruginosa infections.
How Supplied:
Injection: 1 g, 2 g;
Powder for injection: 500 mg, 1 g, 2 g, 6 g, 10 g
Dosage
?IM, IV
Usual infections.
Adults,IM, IV: 1 g q 8-12 hr.
UTIs, uncomplicated.
Adults, IM, IV: 0.25 g q 12 hr.
UTIs, complicated.
Adults, IM, IV: 0.5 g q 8-12 hr.
Uncomplicated pneumonia, mild skin and skin structure infections.
Adults, IM, IV: 0.5-1 g q 8 hr.
Bone and joint infections.
Adults, IV: 2 g q 12 hr.
Serious gynecologic or intra-abdominal infections, meningitis, severe or life-threatening infections (especially in immunocompromised clients).
Adults, IV: 2 g q 8 hr.
Pseudomonal lung infections in cystic fibrosis clients with normal renal function.
IV: 30-50 mg/kg q 8 hr, not to exceed 6 g/day.
Use in neonates, infants, and children.
Neonates, 0-4 weeks, IV: 30 mg/kg q 12 hr, not to exceed the adult dose.
Infants and children, 1 month-12 years, IV: 30-50 mg/kg q 8 hr not to exceed 6 g/day. |
